Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Prostatic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1

Interventions

Specimen Handling 415Magnetic Resonance Spectroscopy 332pembrolizumab 261Biopsy 227Carboplatin 216Cisplatin 179Cyclophosphamide 174Paclitaxel 148Nivolumab 135Gemcitabine 130Radiotherapy 120Dexamethasone 105Bevacizumab 101fludarabine 95Radiation 94Fluorouracil 93Pemetrexed 88Doxorubicin 88Docetaxel 83Rituximab 82venetoclax 81durvalumab 81Oxaliplatin 81Leucovorin 76atezolizumab 68Lenalidomide 66Capecitabine 66Prednisone 65Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × fezolinetant × 30 days × Clear all
NCT06617455 2026-05-06

VEnT

University of Michigan Rogel Cancer Center

Phase 2 Terminated
9 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06917313 2026-05-06

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Yale University

Phase 2 Recruiting
92 enrolled
Breast

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT07568236 2026-05-05

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Chinese University of Hong Kong

Phase 2 Not yet recruiting
54 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡